Lu-177 PSMA Therapy in India — cost, eligibility, outcomes.

What is Lu-PSMA therapy?

Lu-PSMA is the most extensively studied radioligand therapy in prostate cancer. It carries FDA approval (March 2022) and EMA approval (December 2022) under the brand name Pluvicto, and is now established standard of care for PSMA-positive mCRPC after progression on at least one androgen receptor pathway inhibitor. In March 2025, the indication was expanded to allow earlier use, before chemotherapy.

At Theranostic Physicians, we have administered Lu-PSMA since 2018 — with a current cadence of cycles every other Friday at our day-care suite at FMRI Sector 44, Gurugram. Patients are typically discharged within 6 hours of infusion. We offer both Indian-source and German-source variants, with material pricing differences explained below.

How Lu-PSMA works.

Prostate cancer cells overexpress prostate-specific membrane antigen (PSMA) on their surface — with expression intensifying as the disease becomes more aggressive and castration-resistant. PSMA-617 is a synthetic small molecule designed to bind this antigen with high affinity. The therapy exploits that biology in three steps:

• Targeting. PSMA-617 binds selectively to PSMA receptors expressed at 100-to-1000-fold higher density on prostate cancer cells than normal tissue — the same receptors visualised on a 68Ga-PSMA-11 PET/CT scan.
• Delivery. The PSMA-617 ligand is chemically chelated to Lutetium-177, a beta-emitting radioisotope with a 6.7-day physical half-life and a tissue range of approximately 2 mm.
• Cytotoxicity. Once bound and internalised, the Lu-177 emits beta radiation causing DNA double-strand breaks and apoptosis. The 2 mm range treats both the bound cell and microscopic neighbouring disease — the "cross-fire" effect — while sparing distant healthy tissue.

The principal sites of physiological PSMA expression are the salivary glands, kidneys, and small bowel — which explains the signature side effects (xerostomia, occasional renal effects) and the dosimetry priorities.

Who is a candidate?

Lu-PSMA is most effective when patient selection is rigorous. The decision is built on imaging, prior treatment, and organ function. Our centre's standard eligibility criteria, aligned with VISION and PSMAfore trial protocols:

• Histologically confirmed metastatic castration-resistant prostate cancer (mCRPC) with serum testosterone <50 ng/dL on ongoing ADT.
• PSMA-positive disease demonstrated on 68Ga-PSMA-11 PET/CT, with at least one PSMA-avid lesion of uptake intensity greater than liver background, and no PSMA-negative measurable disease that would compete.
• Prior progression on at least one androgen receptor pathway inhibitor (abiraterone, enzalutamide, darolutamide, or apalutamide).
• Either: prior taxane chemotherapy (docetaxel or cabazitaxel) OR chemotherapy is considered inappropriate (the new pre-chemo indication, approved March 2025).
• Adequate organ function: creatinine clearance >50 mL/min, haemoglobin >9 g/dL, platelets >100 × 10⁹/L, AST/ALT <3× upper limit, total bilirubin <1.5× upper limit.
• Life expectancy >6 months and ECOG performance status 0–2.

The six-cycle protocol.

Standard Lu-PSMA therapy at our centre follows the protocol validated in VISION and PSMAfore: six cycles of 7.4 GBq each, six weeks apart, with PSA and imaging monitoring throughout.

Total course duration: approximately 7 to 9 months. Most patients are discharged the same day of each cycle. International patients typically combine each cycle with a 48–72 hour stay in Gurugram.

VISION trial and beyond.

The evidence base for Lu-PSMA-617 is anchored by three pivotal randomised phase 3 trials.

VISION — the landmark trial

VISION¹ randomised 831 men with PSMA-positive mCRPC progressing after at least one ARPI and one taxane to receive Lu-177-PSMA-617 plus standard of care versus standard of care alone. The results, published in the New England Journal of Medicine in 2021, established Lu-PSMA as a new standard of care:

The radiographic progression-free survival was 8.7 months with Lu-PSMA versus 3.4 months with control (HR 0.40). PSA50 response — a 50% or greater decline in PSA — was achieved in 46% of the Lu-PSMA arm versus 7% in control. Objective tumour response by RECIST was 30% versus 2%.

TheraP — versus cabazitaxel

The Australian TheraP² trial compared Lu-PSMA-617 head-to-head with cabazitaxel chemotherapy in PSMA-positive mCRPC after docetaxel. PSA50 response rates were 66% versus 37% in favour of Lu-PSMA, with materially fewer side effects. While overall survival was similar between arms, the response and quality-of-life advantages were clear.

PSMAfore — before chemotherapy

PSMAfore³ tested Lu-PSMA-617 in the pre-chemotherapy setting, after ARPI but before taxane. Radiographic PFS was 12.0 months versus 5.6 months in favour of Lu-PSMA. This trial supported the March 2025 FDA approval expansion to allow earlier use.

Indian real-world experience

Published Indian cohorts — including from our institution and other major Indian centres — report real-world PSA50 response rates of 42–48%, broadly consistent with VISION. Bone-marrow-replaced disease, prior multiple chemotherapy lines, and PSMA-negative components on FDG-PET are consistently associated with lower response.

Indian-source vs German-source Lu-PSMA.

The radioisotope (Lu-177) and the ligand (PSMA-617) are chemically identical between sources. The difference is the manufacturing supply chain, and consequently, price. Both have demonstrated comparable clinical response rates in published Indian cohorts — we offer both and counsel patients on the choice candidly.

Our recommendation is informed by individual clinical context, insurance status, and patient preference. For Indian residents with insurance coverage, German-source is often the default. For self-pay Indian patients, Indian-source dramatically expands access without compromising response. For international patients, German-source is the only option exported.

Cost of Lu-PSMA in India.

Indicative cycle pricing in INR and USD. The numbers below cover the therapy itself — 68Ga-PSMA-11 PET, inpatient room category, and concomitant medication are billed separately by FMRI.

For the deeper cost analysis — including a comparison with international centres in Germany, Australia and the US — see our blog post on the real cost of Lu-177 therapy in India.

What about side effects?

Lu-PSMA is among the better-tolerated systemic cancer therapies in modern oncology — one of the reasons it has displaced cabazitaxel as a preferred option for many mCRPC patients. Most side effects are mild and manageable.

Common (>20% of patients)

• Xerostomia (dry mouth) — the signature side effect of Lu-PSMA, occurring in approximately 39% of patients due to salivary gland PSMA expression. Usually mild to moderate; partially mitigated by cold packs to parotid and submandibular glands during infusion. Cumulative across cycles.
• Fatigue — mild to moderate, typically 1–2 weeks after each cycle.
• Nausea — usually mild; pre-medication with anti-emetics.
• Anaemia and thrombocytopenia — transient reductions in haemoglobin and platelet counts. Monitored every 3 weeks.

Uncommon (1–20%)

• Lymphocytopenia — transient.
• Diarrhoea or constipation — usually mild.
• Loss of appetite — brief.

Rare but serious

• Severe myelosuppression — in <3%. More likely with prior extensive marrow disease or radiation.
• Renal toxicity — uncommon at standard doses, screened for between cycles.
• Myelodysplastic syndrome or acute leukaemia — very rare; reported in <1% in long-term VISION follow-up.

When to consider Ac-225 PSMA.

After completion of 6 cycles of Lu-PSMA, the majority of patients show meaningful PSA decline and radiographic response. For the subset who progress — or who present with very high tumour burden, strong PSMA-PET uptake, and concerning aggressive features — Ac-225 alpha PSMA is the salvage option.

Alpha particles from Ac-225 have a tissue range of 50–100 micrometers — about 100 times shorter than Lu-177's beta range — but they deliver dramatically higher linear energy transfer (LET). The radiobiological effect per disintegration is 5–10× greater than beta radiation. This makes alpha-PSMA particularly useful for:

• Patients who have progressed on Lu-PSMA but retain strong PSMA-PET uptake.
• Bulky bone or visceral metastases where deeper kill is needed despite shorter range.
• Patients with PSMA-low / PSMA-heterogeneous disease where beta cross-fire is insufficient.

Xerostomia is more pronounced with Ac-225 alpha therapy — we discuss this trade-off candidly. Learn more on our Ac-225 PSMA page or discuss escalation at cycle 4 or cycle 6 review.

Next available Lu-PSMA slots.

Lu-PSMA at our centre is scheduled on alternate Fridays. Each cycle is an outpatient day — reach the centre by 8 a.m., discharged by 4 p.m. International patients typically combine each cycle with a 2–3 night stay in Gurugram.